Clinical Significance of the Serum 3′tRF-AlaAGC, Neutrophil to High-Density Lipoprotein Ratio, and Lymphocyte-to-Monocyte Ratio in Breast Cancer with Lymph Node Metastasis

Dongping Mo, Yurong Zhu, Xuelian Mao, Cong Li, Yining Yang, Junyu Zheng, Feng YanJournal of Inflammation Research 2025 · DOI

This study, published in the Journal of Inflammation Research, presents a novel predictive model for identifying lymph node metastasis (LNM) in breast cancer patients. By combining a specific tRNA-derived small RNA (3′tRF-AlaAGC) with two common inflammatory blood ratios—the Neutrophil to High-Density Lipoprotein ratio (NHR) and the Lymphocyte-to-Monocyte ratio (LMR)—the researchers developed a non-invasive "liquid biopsy" tool that could help clinicians assess cancer spread without immediate recourse to invasive surgery.

TL;DR

Researchers have developed a predictive nomogram that combines a novel molecular marker (3′tRF-AlaAGC) with standard inflammatory blood ratios to identify lymph node metastasis in breast cancer. This multi-modal approach offers a non-invasive way to assess the risk of cancer spread with a predictive accuracy (C-statistic) of 0.704.

What Problem Does This Paper Address?

In breast cancer (BC), the spread of the tumor to the lymph nodes (LNM) is a critical turning point for prognosis and treatment planning. Currently, the "gold standard" for identifying LNM is a sentinel lymph node biopsy. While effective, this is an invasive surgical procedure that carries risks of complications like lymphedema, infection, and impaired shoulder mobility.

There is an urgent clinical need for reliable, non-invasive biomarkers that can predict LNM from a simple blood draw. While researchers have previously looked at tRNA-derived small RNAs (tDRs) and systemic inflammatory markers in isolation, this paper addresses the gap in combining these molecular and systemic indicators to create a more robust diagnostic model.

Methods

The study involved 175 patients with breast cancer and 94 healthy controls. The researchers employed a multi-step analytical pipeline:

  1. Molecular Quantification: They used quantitative real-time PCR (qRT-PCR) to measure serum levels of 3′tRF-AlaAGC, a specific fragment of transfer RNA that the authors previously identified as being overexpressed in BC patients.
  2. Inflammatory Profiling: They calculated 13 different inflammatory indicators from standard peripheral blood tests, including NHR and LMR.
  3. Variable Selection: To avoid "overfitting" the model with too many variables, they used Lasso-cox regression to prune the list down to the three most significant predictors.
  4. Model Construction: They used multivariate logistic regression to confirm these three as independent risk factors and then built a nomogram—a visual calculating tool that allows clinicians to sum up points based on a patient's lab results to estimate the percentage risk of LNM.

Datasets

The study utilized a primary clinical dataset collected at the Jiangsu Cancer Hospital between June 2021 and May 2024.

  • Breast Cancer Group: 175 patients (70 with pathologically confirmed LNM, 105 without).
  • Control Group: 94 age-matched healthy women.
  • Clinical Data: Included age, BMI, tumor markers (CEA, CA125, CA153), and full blood counts.

Key Insights and Ideas

  • The Power of tDRs: tRNA-derived fragments (tDRs) are emerging as superior biomarkers to microRNAs because they are shorter, highly stable in serum, and less susceptible to degradation by RNA enzymes.
  • Synergy of Markers: The study found that 3′tRF-AlaAGC levels were significantly higher in patients with LNM compared to those without. Interestingly, NHR was negatively correlated with LMR specifically in the "low" 3′tRF-AlaAGC group, suggesting a complex interplay between the tumor's molecular signaling and the body's systemic immune response.
  • Independent Risk Factors: The researchers identified specific "tipping points" for risk:
  • 3′tRF-AlaAGC > 18.78
    • NHR > 2.94
    • LMR ≤ 5.41
  • The Nomogram Advantage: By integrating these three disparate values into one scoring system, the model provides a more holistic view of the patient's status than any single marker could.

Key Results

  • Predictive Accuracy: The combined model achieved a C-statistic (AUC) of 0.704, indicating a favorable ability to distinguish between LNM and non-LNM cases.
  • Odds Ratios (OR): Multivariate analysis showed that high 3′tRF-AlaAGC (OR: 3.242) and high NHR (OR: 3.305) more than tripled the likelihood of LNM, while high LMR (OR: 0.329) acted as a protective factor.
  • Clinical Utility: The nomogram's scoring system is highly practical. For example, a total score exceeding 275 points on the nomogram corresponds to a greater than 80% probability of LNM.
  • Sensitivity/Specificity: The model demonstrated a sensitivity of 57.14% and a specificity of 77.14%.

Limitations and Future Work

The authors acknowledge several hurdles before this can be used in routine clinical practice:

  • Single-Center Limitation: The data comes from one institution. A multi-center study with a more diverse patient population is necessary to validate the findings.
  • Binary Focus: The study only looked at the presence or absence of LNM. Future research should investigate whether these markers can predict the extent or degree of metastasis (e.g., the number of involved nodes).
  • Prospective Validation: While the results are promising, they need to be confirmed through a large-scale, prospective randomized controlled trial to ensure the model's reliability in real-world diagnostic settings.

Summary updated

Abstract

3'tRF-AlaAGC >18.78, NHR > 2.94, and LMR ≤ 5.41 were the independent risk factors of BC with LNM. The nomogram model incorporating 3'tRF-AlaAGC, NHR and LMR can effectively predict the risk of LNM of BC patients.
BibTeX
@article{mo2025clinical,
  author = {Dongping Mo and Yurong Zhu and Xuelian Mao and Cong Li and Yining Yang and Junyu Zheng and Feng Yan},
  title = {{Clinical Significance of the Serum 3′tRF-AlaAGC, Neutrophil to High-Density Lipoprotein Ratio, and Lymphocyte-to-Monocyte Ratio in Breast Cancer with Lymph Node Metastasis}},
  journal = {Journal of Inflammation Research},
  year = {2025},
  doi = {10.2147/jir.s518232},
}
Figure